BonoFill has the potential to become the first tissue-engineered bone graft to receive regulatory marketing approval. We have already obtained indications for the safety and efficacy of BonoFill during our preclinical and Phase I/II clinical trials for bone tissue regeneration in maxillofacial and orthopedic indications. We are currently planning Phase III clinical trials in these indications. 

MesenCure presents an innovative, cost-effective, and lifesaving treatment option for severe COVID patients suffering from pneumonia and ARDS and a potential treatment for other often life-threatening acute inflammatory diseases. In our Phase II clinical trial, MesenCure was demonstrated to reduce the mortality of severe COVID patients by 68%, from 19% mortality in the control group treated by the SoC only, down to 6% mortality in the test group treated by the conventional care plus MesenCure. These results are unprecedented considering the performance of the best currently available alternative treatment for severe COVID that only reduced mortality by about 10%. 

BonoFill and MesenCure can become viable treatment options due to their safety, ease of administration, and flexibility. BonoFill is an autologous product made from the patient's cells in a closed and highly-controlled culture system requiring minimal manual manipulation. MesenCure, as well, is manufactured using a highly controlled process from cells that do not elicit an immune response. These aspects are expected to improve the quality and safety attributes of the products. 

Our advanced technological platforms and know-how are solid foundations for developing various biotechnological products across the next-generation therapeutics spectrum addressing unmet clinical and market needs. Through many years of research and development, we have gained a unique understanding of the biology, therapeutic utility, and challenges associated with MSCs. 

A wealthy patent estate. The Company directly or through Bonus Therapeutics Ltd. (a wholly-owned subsidiary of Bonus Biogroup Ltd.) holds exclusive rights in seven patent families, including thirty-eight approved patents and seventeen patent applications.